Edition:
United Kingdom

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

12.48EUR
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
€12.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
70,825
52-wk High
€22.50
52-wk Low
€11.25

Latest Key Developments (Source: Significant Developments)

Nanobiotix Q3 revenue down at 33.0‍​ million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - NANOBIOTIX SA ::Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO.  Full Article

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology
Monday, 13 Nov 2017 

Nov 13 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PRESENTED NEW CLINICAL AND PRE-CLINICAL DATA CONFIRMING NBTXR3'S SIGNIFICANT POTENTIAL ROLE IN IMMUNO-ONCOLOGY AT SITC ANNUAL MEETING.‍PATIENTS TREATED WITH NBTXR3 AND RADIOTHERAPY SHOW A MARKED INCREASE OF PD1 AND CD8 INFILTRATION​.‍NBTXR3 ACTIVATED BY RADIOTHERAPY INDUCES SIGNIFICANT ADAPTIVE IMMUNE PATTERN VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH SOFT TISSUE SARCOMA​.‍STRONG DATA TO SUPPORT RATIONAL FOR UPCOMING CLINICAL TRIAL IN COMBINATION WITH CHECK POINT INHIBITORS​.‍PRECLINICAL DATA ON DIFFERENT ANIMAL MODELS CONFIRM BROAD POTENTIAL OF NBTXR3 AS A PRIMER OF IMMUNE RESPONSE​.  Full Article

Nanobiotix completes new share issue for about 27.2 million euros
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES.‍ISSUES OF 1,941,789 NEW SHARES, PAR VALUE EUR 0.03​.‍ISSUE PRICE OF NEW SHARES HAS BEEN SET AT EUR 14.00 PER SHARE, REPRESENTING AN 18% DISCOUNT​.‍TRADING OF THE NEW SHARES TO START ON EURONEXT PARIS ON NOVEMBER 2, 2017​.  Full Article

Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3
Monday, 23 Oct 2017 

Oct 23 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA.‍LAST PATIENTS ARE EXPECTED TO START TREATMENT IN TWO TO THREE WEEKS​.‍EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL IN SOFT TISSUE SARCOMA IN FIRST HALF OF 2018​.  Full Article

Nanobiotix H1 loss after tax widens to 10.2 million euros
Wednesday, 31 Aug 2016 

Nanobiotix SA : H1 loss after tax of 10.2 million euros ($11.38 million) versus 7.8 million euros a year ago .Cash balance as of 30 June 2016 was 25 million euros, as per expectations.  Full Article

Nanobiotix Q2 revenue jumps to 0.9 million euros
Wednesday, 13 Jul 2016 

Nanobiotix SA :Q2 revenue EUR 0.9 million ($1.00 million) versus EUR 46,000 year ago.  Full Article

Nanobiotix Q1 revenue down at 45,847 euros
Friday, 13 May 2016 

Nanobiotix SA :Q1 revenue 45,847 euros ($51,775.02) versus 46,991 euros year ago.  Full Article

Nanobiotix starts new research program in Immuno Oncology with NBTXR3​
Tuesday, 5 Jan 2016 

Nanobiotix SA:Nanobiotix starts a new research program in Immuno Oncology with its lead product NBTXR3.  Full Article

Nanobiotix SA: FDA approval on NBTXR3 in study in prostate cancer
Monday, 4 Jan 2016 

Nanobiotix SA:FDA approved investigational new drug for NBTXR3 in a new clinical study in prostate cancer.FDA approval enables company to initiate a phase I/II prospective, open-label, two cohorts and non-randomized trial, in large prostate cancer patient population.  Full Article

BRIEF-Nanobiotix Q3 revenue down at 33.0‍​ million euros

* Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO Source text: http://bit.ly/2zKWYHz Further company coverage: (Gdynia Newsroom)